## US Family Health Plan Prior Authorization Request Form for

calcipotriene 0.005% betamethasone 0.064% ointment (**Taclonex**, **generic**) calcipotriene 0.005% betamethasone 0.064% cream (**Wynzora**) calcipotriene0.005% betamethasone 0.064% foam (**Enstilar**)

To be completed and signed by the prescriber. To be used only for prescriptions which are to be filled through the Department of Defense (DoD) US Family Health Plan Pharmacy Program. US Family Health Plan is a TRICARE contractor for DoD.

The completed form may be faxed to 855-273-5735

OR.

The patient may attach the completed form to the prescription and **mail** it to:

Attn: Pharmacy, 77 Warren St, Brighton, MA 02135

## QUESTIONS? Call 1-877-880-7007

•				•		
Step	Please complete patient and physician information (please print):					
1	Patient Name:	Physician Name:				
	Address:	_	Address:	_		
	Character ID #	_	Dhana #:			
	Sponsor ID #  Date of Birth:	Phone #: Secure Fax #:				
Step						
_ •	Please complete the clinical assessment:					
2	<ol> <li>This agent has been identified as having cos effective alternatives including the following</li> </ol>					
	<ul> <li>for the calcipotriene (vitamin D analog) component, alternatives include generic</li> </ul>		☐ Acknowledged			
	calcipotriene 0.005% cream, ointment, an solution;	d	Proceed to question 2			
	<ul> <li>for the betamethasone (high-potency topic corticosteroid) component, alternatives in clobetasol propionate 0.05% ointment, cresolution, and shampoo and fluocinonide cream, ointment, and solution.</li> </ul>	nclude eam,				
	These agents are available without a PA. Please consider changing the prescription to one of these agents.					
	2. Is the patient 12 years of age or older?		□ Yes	□ No		
			Proceed to question 3	STOP		
			·	Coverage not approved		
	For which diagnosis is the requested medication being prescribed?		☐ Plaque psoriasis – Proceed to question <b>4</b>			
			☐ Other – STOP Coverage not approved			
	4. Has the patient experienced an adverse reac		□ Yes	□ No		
	failure from at least a 2 week trial of at least high-potency topical corticosteroid (for exar		Proceed to question 5	STOP		
	clobetasol 0.05% ointment, cream, solution, shampoo; fluocinonide 0.05% cream, ointme solution)?			Coverage not approved		

## US Family Health Plan Prior Authorization Request Form for calcipotriene 0.005% betamethasone 0.064% ointment (**Taclonex, generic**) calcipotriene 0.005% betamethasone 0.064% cream (**Wynzora**) calcipotriene0.005% betamethasone 0.064% foam (**Enstilar**)

	5.	Has the patient tried and failed or had an adverse reaction to calcipotriene 0.005% ointment, cream, OR solution?	☐ Yes Proceed to question 6	□ No STOP Coverage not approved			
	6.	Has the patient tried and failed an individual calcipotriene agent (calcipotriene 0.005% ointment, cream or solution) AND an individual high-potency topical corticosteroid agent used concurrently?	☐ Yes Proceed to question <b>7</b>	□ No STOP Coverage not approved			
	7.	Please explain why this agent is required and the patient cannot take the available alternatives.					
			Sign and o	date below			
Step 3	I certify the above is true to the best of my knowledge. Please sign and date:						
		Prescriber Signature	Date				
				[24 Fahruan, 2024]			

[24 February 2021]